Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
| Revenue (TTM) | $87.81M |
| Gross Profit (TTM) | $51.07M |
| EBITDA | $7.37M |
| Operating Margin | -2.90% |
| Return on Equity | -89.90% |
| Return on Assets | 1.58% |
| Revenue/Share (TTM) | $19.64 |
| Book Value | $1.63 |
| Price-to-Book | 5.19 |
| Price-to-Sales (TTM) | 0.43 |
| EV/Revenue | 0.868 |
| EV/EBITDA | 55.96 |
| Quarterly Earnings Growth (YoY) | -80.30% |
| Quarterly Revenue Growth (YoY) | 11.10% |
| Shares Outstanding | $4.55M |
| Float | $3.68M |
| % Insiders | 9.39% |
| % Institutions | 41.90% |
Volatility is currently expanding
HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will participate in Canaccord Genuity's MedTech, Diagnostics, and Digital Health and Services Forum on November 11th, 2026.
HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company's ongoing research, development, and new product roadmaps.
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events.
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HBIO and any ticker you trade — then tracks every position and per-strategy win rate.
